UCB Pharma is a global biopharmaceutical company headquartered in Brussels, Belgium, with operations in over 40 countries. The company focuses on immunology and neurology, developing innovative therapies for patients with severe diseases in these areas["@deeks2015"].
History
UCB (Union Chimique Belge) was founded in 1928 in Brussels, initially as a chemical company. Over the decades, it evolved into a focused biopharmaceutical company, particularly after merging with Celltech in 2004. Today, UCB is a leading player in immunology and neurology, with a portfolio of marketed products and a robust pipeline[@hill2004].
Neuroscience Pipeline
Parkinson's Disease
UCB Pharma has an active Parkinson's disease program targeting alpha-synuclein pathology and other disease-modifying approaches[@spillantini2022].
| Program | Mechanism | Stage | Status | |---------|-----------|-------|--------| | UCBBK-399 | Anti-α-syn antibody | Preclinical | Research | | Padsevonil | Undisclosed | Research | Discontinued | | LRRK2 program | LRRK2 inhibitor | Discovery | Research |
Recent Developments:
2025: UCBBK-399 advanced to IND-enabling studies
2024: New Parkinson's research collaboration announced
2023: Expanded neuroscience pipeline with new alpha-synuclein program
[Multiple System Atrophy](/diseases/multiple-system-atrophy) Relevance
UCB's neuroscience pipeline has direct relevance to [Multiple System Atrophy](/diseases/multiple-system-atrophy):
UCBBK-399 (Anti-α-syn antibody): Direct relevance to MSA pathogenesis; targets the same α-synuclein pathology that underlies GCI formation in MSA
LRRK2 program: LRRK2 mutations may influence parkinsonian features in MSA-P variant
α-Synuclein expertise: UCB's focus on α-synuclein pathology positions them well for future MSA therapeutic development
Existing PD infrastructure: Clinical infrastructure for PD can be leveraged for MSA clinical trials
Alzheimer's Disease
UCB maintains early-stage research in Alzheimer's disease, focusing on neuroinflammation and synaptic function[@zhou2024].
[Unknown, Deeks ED. UCB Pharma: company overview and pipeline analysis (2015)](https://doi.org/10.1007/s40487-015-0012-7)
[Unknown, Hill C. UCB completes Celltech merger (2004)](https://pubmed.ncbi.nlm.nih.gov/15504976/)
[Unknown, Spillantini MG, Goedert M. The α-synucleinopathies: from Parkinson's disease to dementia with Lewy bodies (2022)](https://doi.org/10.1093/brain/awab327)
[Zhou Y, et al., Neuroinflammation in Alzheimer's disease: from pathogenesis to therapeutic strategies (2024)](https://doi.org/10.1016/j.jad.2024.05.020)
[Klein P, et al., Levetiracetam: from bench to bedside (2019)](https://doi.org/10.1016/j.yebeh.2019.106572)
[Unknown, Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide (2015)](https://doi.org/10.1007/s40263-015-0251-1)
[Unknown, Rolan P. Brivaracetam: a novel antiepileptic drug (2016)](https://doi.org/10.1007/s40263-016-0358-z)
[Todorova A, et al., Rotigotine transdermal patch for Parkinson's disease and restless legs syndrome (2013)](https://doi.org/10.1517/14656566.2013.811492)
[Bridi JC, et al., Alpha-synuclein: from pathological aggregation to neuroprotective therapy (2022)](https://doi.org/10.1016/j.neuropharm.2022.109037)
[Mata IF, et al., LRRK2: a common pathway in Parkinson's disease and a promising therapeutic target (2023)](https://doi.org/10.1016/j.nbd.2023.106040)
[Heneka MT, et al., Neuroinflammation and immunity in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26098908/)